Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
about
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerA common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.BRCA1-Dependent Translational Regulation in Breast Cancer Cells.Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profilesPrognostic significance of TOP2A gene dosage in HER-2-negative breast cancerTopoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutationsAnti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitriesTranslating next generation sequencing to practice: opportunities and necessary steps.Wip1 phosphatase in breast cancer.History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.Enhanced expression of retinoic acid receptor alpha (RARA) induces epithelial-to-mesenchymal transition and disruption of mammary acinar structures.Sparse multivariate factor analysis regression models and its applications to integrative genomics analysis.TOP2A amplification in breast cancer in the absence of that of HER-2: myth or reality?Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications.Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
P2860
Q28085413-3D905D0C-0097-4671-9BF1-DFDEB3C79FE2Q33739397-D7B98939-BCA1-4E3D-8D02-70514F4CB3ABQ34010867-D75222F6-E388-41D8-B94E-94E101ED953BQ34421158-7CD6C448-4F61-4413-84DF-88104F7737E9Q34785674-4AE9148C-FE6C-43A5-B6F2-5752F849E698Q34923304-F42DF651-8AA5-433F-92C5-AE250635168AQ35872476-1D3FA213-F670-46A0-8140-67B830FB654CQ35889673-FFEB0DF0-3EDA-47F4-948C-B8BB11182A59Q36349584-238F39DA-C034-4037-BD05-24FFF1D2A9E6Q36402262-4A8DCE26-E45D-449D-87B9-2C7CB282BA87Q37201218-1505496D-199B-4FE1-9877-4145589A0C53Q37594358-393FF398-29D1-4E2D-9EBC-0E0F93D7C315Q37687445-B00FC554-65EC-4B7A-AE8D-6CDCDC4C2D6BQ37710032-583AB4A8-3A37-45A0-9230-69AC6FBC6D5CQ38114641-7F470855-902E-4961-A39D-C55E8892119CQ38266298-9714C5EF-824B-4B28-B9FD-755ADC349729Q38947077-33BED925-D784-46A6-AE49-7EB57E5FFBB7Q38949355-CE5FF26D-84C6-464F-A45C-1A4BFCE8C6CDQ39175219-110EE9F1-2E14-421A-BE5C-3065FEE55004Q42425720-30BA36BC-F1EC-489B-BDD9-B7E9A386FAD1Q53658742-AE54E976-EF39-478A-8909-796C34C277BDQ55396428-B5CCA26F-D9F3-461E-85A8-737D7DFC5676Q58797604-F8EE5097-608E-49E2-A6BC-67B6CB21995A
P2860
Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Quantification and clinical re ...... or 2-amplified breast cancers.
@ast
Quantification and clinical re ...... or 2-amplified breast cancers.
@en
type
label
Quantification and clinical re ...... or 2-amplified breast cancers.
@ast
Quantification and clinical re ...... or 2-amplified breast cancers.
@en
prefLabel
Quantification and clinical re ...... or 2-amplified breast cancers.
@ast
Quantification and clinical re ...... or 2-amplified breast cancers.
@en
P2093
P2860
P356
P1476
Quantification and clinical re ...... or 2-amplified breast cancers.
@en
P2093
Anne-Claire Laberenne
Caroline Bascoul-Mollevi
Frédéric Fina
Pierre-Jean Lamy
Pierre-Marie Martin
William Jacot
P2860
P2888
P356
10.1186/BCR2824
P577
2011-02-02T00:00:00Z
P5875
P6179
1045902430